Health Care Financing Administration (HCFA) to reimburse investigational device exemption (IDE) devices:
This article was originally published in Clinica
The US Department of Health & Human Services is expected to announce soon that the Health Care Financing Administration will reimburse new investigational technologies, reports Clinica's Washington correspondent, Duffy Miller. As indicated at the Utah International Medical Congress last month (see Clinica No 669/70, p 9), the FDA supports Medicare payment for "evolutionary" IDEs. HCFA is expected to be required to pay for Medicare patients enrolled in clinical trials of "advanced and promising" technology. Only products representing "refinements" of approved devices would be reimbursable - the FDA will assist HCFA in identifying these products. Medicare estimates that some $7 million will be paid next year for IDEs.
You may also be interested in...
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.